Ipamorelin fires one clean pulse of growth hormone — and skips the cortisol spike older peptides cause.

The short version

Ipamorelin is a tiny lab-made peptide — just five amino acids strung together. Its one job in the research is to nudge a gland at the base of your brain (the pituitary) into releasing a burst of growth hormone, or GH. It does this by flipping a switch called the ghrelin receptor, the same switch your body's natural hunger hormone uses. What makes ipamorelin stand out is how tidy the burst is: in animal studies it raised GH strongly but left stress hormones like cortisol alone, which older peptides could not do. People in research-use communities reach for it hoping for deeper sleep, faster recovery, and a slow shift toward leaner body composition — but here is the honest part: the one real human trial (for slow bowels after surgery) did not work, and ipamorelin has never been approved as a medicine anywhere. This is a reading site, not a clinic — what people report, including the downsides, lives on the effects page.

What the ipamorelin literature actually shows

Ipamorelin (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a selective growth hormone secretagogue — a compound built to make the pituitary release growth hormone (GH) on demand ^[1]. In its founding 1998 characterization it released GH potently in rat pituitary cells, anaesthetised rats, and conscious swine, with a swine ED50 of 2.3 nmol/kg — slightly more potent than the older peptide GHRP-6 at 3.9 nmol/kg ^[1]. The headline was not the potency. It was the silence everywhere else: even at doses more than 200 times its GH ED50, ipamorelin did not push ACTH or cortisol above the level a plain GHRH signal produces ^[1]. That selectivity — a strong GH pulse, almost nothing on the stress-hormone axis — is the single feature every later study and every community thread comes back to.

The GH pulse it triggers is fast and discrete. In the one human pharmacokinetic study, GH peaked roughly 40 minutes after an intravenous dose and ipamorelin cleared with a terminal half-life of about 2 hours ^[2]. Downstream, GH is supposed to drive the liver to make IGF-1 (insulin-like growth factor 1), the messenger behind much of GH's tissue effect — but in short rodent studies IGF-1 did not always move, which is part of why the GH-axis story here is more nuanced than 'peptide in, IGF-1 up' ^[4].

Selectivity is the whole point

Older growth-hormone-releasing peptides worked, but they were messy: GHRP-6 and GHRP-2 raised GH and also nudged cortisol and prolactin. Ipamorelin was engineered out of GHRP-1 by snipping a central dipeptide, and the result was the first GH secretagogue clean enough to release GH without that collateral hormone spill ^[1]. In plain terms, it is a sharper tool — it pulls one lever (GH) and mostly leaves the others alone ^[1]. That is why it shows up in research conversations about sleep and recovery rather than as a blunt hormone hammer.

The receptor it hits is GHS-R1a — the ghrelin receptor, the same one your body's natural 'hunger hormone' uses. Activating it on the pituitary's GH-making cells (somatotrophs) opens calcium channels inside the cell and triggers a GH burst ^[4]. Because ghrelin's receptor also sits on appetite circuits in the brain, a side effect of pulling this lever can be feeling hungrier — a class trait covered honestly on the effects page.

Where the human evidence stops

Here is the line the marketing usually blurs. Ipamorelin has exactly one published Phase 2 human trial. It enrolled 114 adults recovering from bowel surgery, gave 0.03 mg/kg intravenously twice daily, and tested whether it sped the return of normal gut function — and it missed its main goal: a median 25.3 hours to first tolerated meal versus 32.6 hours on placebo, which was not statistically significant (p=0.15) ^[3]. No serious ipamorelin-specific safety signal showed up in that short window, but efficacy was simply not demonstrated ^[3]. There is no Phase 3 trial and no approval, anywhere ^[3].

That is the honest backbone of this site. The mechanism is real and elegant. The rodent data is genuine. The one human efficacy test came back negative. Everything else you read — anti-aging, fat loss, the popular CJC-1295 stack — leans on mechanism and animal work, not human outcome trials ^[3]. Dig into the studies on Ipamorelin research, the reported effects on Ipamorelin effects, and the source list on Ipamorelin references.